Lipids with the structural backbone of sphingosine are defined as sphingolipids. Sphingolipid (SPL) metabolism is complex, not only numerous molecules are involved in the SPL pathway, but also it can be affected by many stimuli, agents or endocrine regulation. SPLs are components of the cell membrane; it also works as bioactive mediators regulating cell death and survival. Literature shows that dysregulation of SPL metabolism contributes to the initiation and development of cancer which is characterized as uncontrolled cell proliferation or invasion/metastasis in severe cases. Specifically, SPL metabolism dysfunction appears in several kinds of cancer mediated by endocrine disorders. Early diagnosis and prognosis evaluation in cancer are still difficult to do by now, specific changes of SPL molecules in cancer, especially in serum, might be used in early diagnosis and prognosis evaluation. Additionally, dysregulation of SPL metabolism is also involved in drug resistance which is one of the challenges in cancer chemotherapy.
This research topic aims to provide insight into several facets of the connections between sphingolipid metabolism and cancer, including initiation, development, invasion/metastasis, early diagnosis, prognosis evaluation, chemotherapy resistance.
• Dysregulation of sphingolipids metabolism and the initiation, development of cancer
• Dysregulation of sphingolipids metabolism involved in cancer metastasis
• Dysregulation of sphingolipids metabolism and chemotherapy resistance
• The value of sphingolipid molecules in early diagnosis and prognosis evaluation
• Cancer drug design targeting sphingolipid molecules
• Dysregulation of sphingolipids metabolism mediated by endocrine regulation and cancer
Lipids with the structural backbone of sphingosine are defined as sphingolipids. Sphingolipid (SPL) metabolism is complex, not only numerous molecules are involved in the SPL pathway, but also it can be affected by many stimuli, agents or endocrine regulation. SPLs are components of the cell membrane; it also works as bioactive mediators regulating cell death and survival. Literature shows that dysregulation of SPL metabolism contributes to the initiation and development of cancer which is characterized as uncontrolled cell proliferation or invasion/metastasis in severe cases. Specifically, SPL metabolism dysfunction appears in several kinds of cancer mediated by endocrine disorders. Early diagnosis and prognosis evaluation in cancer are still difficult to do by now, specific changes of SPL molecules in cancer, especially in serum, might be used in early diagnosis and prognosis evaluation. Additionally, dysregulation of SPL metabolism is also involved in drug resistance which is one of the challenges in cancer chemotherapy.
This research topic aims to provide insight into several facets of the connections between sphingolipid metabolism and cancer, including initiation, development, invasion/metastasis, early diagnosis, prognosis evaluation, chemotherapy resistance.
• Dysregulation of sphingolipids metabolism and the initiation, development of cancer
• Dysregulation of sphingolipids metabolism involved in cancer metastasis
• Dysregulation of sphingolipids metabolism and chemotherapy resistance
• The value of sphingolipid molecules in early diagnosis and prognosis evaluation
• Cancer drug design targeting sphingolipid molecules
• Dysregulation of sphingolipids metabolism mediated by endocrine regulation and cancer
